Download TACROLIMUS (FK506) AUGUST 12, 2013

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Blood donation wikipedia , lookup

Jehovah's Witnesses and blood transfusions wikipedia , lookup

Hemorheology wikipedia , lookup

Plateletpheresis wikipedia , lookup

Blood type wikipedia , lookup

Blood bank wikipedia , lookup

Men who have sex with men blood donor controversy wikipedia , lookup

Transcript
CHANGE
TACROLIMUS (FK506)
TACROLIMUS (FK 506)
EFFECTIVE
AUGUST 12, 2013
LABTX00027
Effective August 12, 2013, the clinical laboratory will change methodologies for
Tacrolimus (FK506). The switch will be from the Diasorin PRO-TRAC II FK506 ELISA to
the Abbott ARCHITECT Tacrolimus Chemiluminescent Microparticle Immunoassay.
Tacrolimus levels are used to help maintain effective immunosuppression.
The Abbott ARCHITECT assay is used by over 75% of the clinical labs that submit
results for CAP surveys. Manufacturer results compared the ARCHITECT method to
LC/MS/MS with a slope of 1.07, an intercept of 0.22, and a correlation coefficient of 0.92.
The 95% CI for ng/mL difference bias was 0.31 to 0.71 ng/mL.
In house validation studies showed the Abbott ARCHITECT assay to recover
results lower than the previous ELISA assay. Deming regression studies showed the
Abbott ARCHITECT method when compared to the ELISA to have a slope of 0.75 with a
y-intercept of 2.4 ng/mL. The correlation coefficient was 0.96.
Reference Interval:
Dependent upon individualized treatment protocol.
Many factors influence the determination of appropriate tacrolimus blood levels at any
individual transplant center and for any single patient. The results from an update of the
Lake Louise Consensus indicate that whole blood concentrations of tacrolimus should be
monitored and blood levels should be maintained in the range of 5 to 15 ng/mL for
optimal efficacy and minimal toxicity in kidney transplant recipients. Higher
1
concentrations are associated with an increased incidence of adverse effects.
Acceptable sample types will continue to be:
EDTA whole blood: 4 mL
Testing performed in:
Specialty Testing Center Toxicology/Special Chemistry Department daily. Specimens
should be received in SESP lab by 10 am.
1. Oellerich M, Armstrong VW, Schutz E, Shaw LM. Therapeutic Drug Monitoring of Cyclosporine
and Tacrolimus. Clinical Biochemistry, Vol. 31, No.5, 309-316, 1998.
For clinical and technical questions please call Dr. Ishwarlal Jialal (734-6590) or Teri Cook
(734-0283). For other questions or additional information please contact Laboratory Client
Services at 916-734-7373 or email [email protected].
LIS mnemonic: TFK506
www.testmenu.com/ucdavis